Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease-Reference-Cited by-同舟云学术

Antibodies‐to‐infliximab accelerate clearance while dose intensification reverses immunogenicity and recaptures clinical response in paediatric Crohn’s disease

Published:2021-12-22 Issue:5 Volume:55 Page:593-603
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Colman Ruben J.¹^ORCID,Xiong Ye²,Mizuno Tomoyuki²³^ORCID,Hyams Jeffrey S.⁴^ORCID,Noe Joshua D.⁵,Boyle Brendan⁶,D’Haens Geert R.⁷,Limbergen Johan⁸^ORCID,Chun Kelly⁹,Yang Jane⁹,Rosen Michael J.¹³^ORCID,Denson Lee A.¹³^ORCID,Vinks Alexander A.²³^ORCID,Minar Phillip¹³^ORCID

Affiliation:

1. Gastroenterology, Hepatology, and Nutrition Cincinnati Children’s Hospital Medical Center Cincinnati OH USA

2. Clinical Pharmacology Cincinnati Children’s Hospital Medical Center Cincinnati OH USA

3. University of Cincinnati College of Medicine Cincinnati OH USA

4. Gastroenterology, Hepatology and Nutrition Connecticut Children’s Medical Center Hartford CT USA

5. Gastroenterology, Hepatology and Nutrition Children’s Hospital of Wisconsin Milwaukee WI USA

6. Gastroenterology, Hepatology and Nutrition Nationwide Children’s Hospital Columbus OH USA

7. Gastroenterology and Hepatology Amsterdam UMC Amsterdam The Netherlands

8. Pediatric Gastroenterology Emma Children’s Hospital Amsterdam UMC Amsterdam The Netherlands

9. Esoterix, LabCorp Calabasas Hills CA USA

Funder

National Institute of Diabetes and Digestive and Kidney Diseases

National Center for Advancing Translational Sciences

Eunice Kennedy Shriver National Institute of Child Health and Human Development

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/apt.16733

Reference39 articles.

1. Inflammatory Bowel Disease in Children and Adolescents

2. Influence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease

3. Combination Therapy With Infliximab and Azathioprine Improves Infliximab Pharmacokinetic Features and Efficacy: A Post Hoc Analysis

4. Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

5. HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn’s Disease

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Challenges in IBD Research 2024: Pragmatic Clinical Research;Inflammatory Bowel Diseases;2024-05-01

2. From Dose to Exposure: Shifting the Paradigm of Pediatric Clinical Pharmacology Research and Education;Clinical Pharmacology & Therapeutics;2024-04-30

3. Impact of HLA-DQA1*05 Genotype in Immunogenicity and Failure to Treatment with Tumour Necrosis Factor-alpha Antagonists in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis;Journal of Crohn's and Colitis;2024-01-14

4. Infliximab Monotherapy vs Combination Therapy for Pediatric Crohn’s Disease Exhibit Similar Pharmacokinetics;Inflammatory Bowel Diseases;2024-01-03

5. Can Proactive Therapeutic Drug Monitoring Overcome Pharmacogenomic-Associated Immunogenicity to Anti-Tumor Necrosis Factor Agents?;Clinical Gastroenterology and Hepatology;2024-01